Health
First-in-human study with novel antisense oligonucleotide proves promising – Medical Xpress
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarcti…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics.
“Based on documented, promising therapeutic potential, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a f…
-
General23 hours agoLiberal Party’s climate policy a huge headache for state and federal leaders
-
General9 hours agoTrump considering ‘world tariff’ of 15-20 per cent
-
General22 hours agoLet’s abandon the cult of Net Zero
-
General19 hours agoWyndham City Council referred to IBAC as MP claims tens of millions ‘flushed down the toilet’ on failed IT project